Business Wire

ZAYED-SUSTAINABILITY

23.1.2023 14:13:40 CET | Business Wire | Press release

Share
Zayed Sustainability Prize Opens Submissions for 2024 Cycle

The Zayed Sustainability Prize, the UAE’s pioneering global award for recognising excellence in sustainability, has officially announced that the 2024 cycle is now open for submissions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230123005377/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

January 16, 2023: Winners of the 2023 Zayed Sustainability Prize stand on stage with global leaders. (Photo: AETOSWire)

Submissions will be accepted until 2nd May 2023 through the Prize’s online portal. Small to medium enterprises, nonprofit organisations and high schools with sustainability solutions are invited to submit an entry for consideration in one of the five categories of Heath, Food, Energy, Water and Global High Schools.

The Prize’s 2023 award cycle received a record-breaking 4,538 applications from 152 countries, marking a 13% increase in submissions compared to the previous cycle.

Commenting on the launch of the 2024 submissions cycle, H.E. Dr. Sultan Ahmed Al Jaber, UAE Minister of Industry and Advanced Technology and Director General of the Zayed Sustainability Prize, said, “This year, the Prize celebrates 15 years of honouring the legacy of the UAE’s Founding Father, Sheikh Zayed, and accelerating sustainable development and humanitarian impact around the world. Since 2008, the Prize has, through the visionary leadership of the United Arab Emirates, facilitated the delivery of sustainable solutions to vulnerable communities, improving access to reliable and affordable energy, safe drinking water, nutritious food and quality healthcare for millions. These efforts directly support the UAE’s broader aims to encourage international collaboration and build a sustainable and prosperous global economy.”

H.E. Al Jaber added, “Importantly, the Prize has prioritised youth and empowers young people to lead in sustainable development. Through the Global High Schools category, the Prize provides opportunities for young people to build their skills in sustainability and leadership and encourages them to take an active role in supporting their communities and driving climate action.

“The Zayed Sustainability Prize helps organisations and schools scale their solutions, enabling them to realise even greater impact and catalyse positive, transformational change. To date, the Prize has impacted the lives of over 378 million people around the world, including in Vietnam, Nepal, Sudan, Ethiopia, Maldives and Tuvalu.”

The Prize’s US$3 million fund rewards winners US$600,000 in each category. The Global High Schools category is split into six world regions, with each school able to claim up to US$100,000 to start or further expand their project. The six world regions of the Global High Schools category are The Americas, Europe & Central Asia, Middle East & North Africa, Sub-Saharan Africa, South Asia, and East Asia & Pacific.

Inspired by the sustainability and humanitarian legacy of the UAE’s Founding Father, Sheikh Zayed bin Sultan Al Nahyan, the Prize has, to date, recognised a total of 106 winners whose solutions or student-led school projects have positively transformed the lives of millions.

While the submission forms vary per category, core elements of each entry lie in the innovative, impactful and inspirational ways in which the proposed technology, applications and solutions aim to improve wellbeing and sustainability.

For the Health, Food, Energy, and Water categories, organisations should demonstrate that they are improving access to essential products or services and have a long-term vision for better living and working conditions. For the Global High Schools category, their projects should be student–led, with emphasis placed on the students being actively involved in the planning, implementation, and monitoring processes.

The Zayed Sustainability Prize has a three-stage evaluation process, beginning with the due diligence conducted on all submissions to ensure that they meet the Prize’s evaluation criteria. This identifies the qualified entries and results in the selection of eligible candidates. Following this, evaluations are undertaken by a Selection Committee consisting of category-specific panels of independent international experts. From this shortlist of candidates, the finalists are chosen and then sent to the Prize Jury who unanimously elect the winners, across all five categories.

Winners of the 2024 Zayed Sustainability Prize will be announced at an Awards Ceremony during the COP28 Climate Summit.

For more information, visit www.ZayedSustainabilityPrize.com

Boilerplate

The Zayed Sustainability Prize is the UAE’s pioneering global award in sustainability and a tribute to the legacy of the late founding father of the UAE, Sheikh Zayed bin Sultan Al Nahyan. Established in 2008, the Zayed Sustainability Prize aims to drive sustainable development and humanitarian action by recognising and rewarding small and medium-sized enterprises, nonprofit organisations, and high schools that are delivering impactful, innovative and inspiring solutions in the categories of Health, Food, Energy, Water and Global High Schools.

In 2023, the Zayed Sustainability Prize is celebrating 15 years of delivering humanitarian impact around the globe. Through its 106 winners, the Prize has positively impacted the lives of over 378 million people across 150 countries.

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230123005377/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye